PM

Pallav Mahesh Shah

Active Director Director DIN 05303168
DIN 05303168 First appointment Apr 2012 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Apr 2012
Shareholding value •••• Premium profile

About Pallav Mahesh Shah

Data last updated:

Pallav Mahesh Shah is a Director at Aurochem Laboratories (India) Private Limited (since 2015), Director at Regaliz Medicare Limited (since 2016) and Director at Aurochem Pharmaceuticals (India) Private Limited (since 2015). The companies operate in Pharma, Healthcare and Internet. The 3 current companies with reported revenue have a combined latest revenue of ₹297 Cr; the largest is Aurochem Laboratories (India) Private Limited at ₹122 Cr (FY 2024). Earlier, Pallav Mahesh Shah was a Director at Glopharm Laboratories Private Limited (2012–2016) and Director at Bryan & Candy (I) Private Limited (2019–2021).

DIN 05303168
Primary Designation Director
Industry Pharma
First Appointment 01 Apr 2012
Oldest Company Age 31 yrs
Largest company Aurochem Laboratories (India) Private Limited · ₹122 Cr (FY 2024)
Combined revenue ₹297 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Apr 20151997₹122 Cr (FY 2024)Active
Regaliz Medicare Limited U74999MH2016PLC285743
Director09 Sep 20162016₹99.88 Cr (FY 2025)Active
Director01 Apr 20151994₹75.57 Cr (FY 2024)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Apr 20122011₹1.32 Cr (FY 2024)Active
Bryan & Candy (I) Private Limited U73100MH2019PTC328736
Director31 Jul 20192019₹8.51 Cr (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Aurochem Pharmaceuticals (India) Private Limited
Aurochem Laboratories (India) Private Limited
Regaliz Medicare Limited
Glopharm Laboratories Private Limited
Premium access

Shareholding and investment profile for Pallav Mahesh Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pallav Mahesh Shah

Pallav Mahesh Shah currently holds 3 directorships: Aurochem Laboratories (India) Private Limited (Director, since 01 Apr 2015, revenue ₹122 Cr (FY 2024)); Regaliz Medicare Limited (Director, since 09 Sep 2016, revenue ₹99.88 Cr (FY 2025)); Aurochem Pharmaceuticals (India) Private Limited (Director, since 01 Apr 2015, revenue ₹75.57 Cr (FY 2024)).

Pallav Mahesh Shah was first appointed on 01 Apr 2012 as Director at Glopharm Laboratories Private Limited. The most recent appointment on record is 31 Jul 2019 at Bryan & Candy (I) Private Limited.

The 3 current companies of Pallav Mahesh Shah that report revenue have a combined latest revenue of ₹297 Cr: Aurochem Laboratories (India) Private Limited ₹122 Cr (FY 2024); Regaliz Medicare Limited ₹99.88 Cr (FY 2025); Aurochem Pharmaceuticals (India) Private Limited ₹75.57 Cr (FY 2024).

Pallav Mahesh Shah held 2 earlier board appointments: Glopharm Laboratories Private Limited (Director, 01 Apr 2012 to 20 Sep 2016); Bryan & Candy (I) Private Limited (Director, 31 Jul 2019 to 16 Aug 2021).

The current boards of Pallav Mahesh Shah's companies include Dipak Dolatrai Desai (Aurochem Laboratories (India) Private Limited), Piyush Mansukhlal Shah (Aurochem Laboratories (India) Private Limited), Pravinchandra Bhikhabhai Desai (Aurochem Laboratories (India) Private Limited), Himanshu Pravin Desai (Regaliz Medicare Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available